Semax

Molecular Profile

Type

Synthetic peptide (heptapeptide)

Molecular formula

C37H51N9O10S

Molecular weight

813.93 g/mol

CAS number

80714-61-0

Amino acids

7

Sequence

Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)

Modification

C-terminal Pro-Gly-Pro tripeptide extension of the ACTH(4-7) core; confers resistance to prolyl endopeptidase degradation; PGP is the principal brain metabolite.

Mechanism & Target Class

A linear heptapeptide consisting of the ACTH(4-7) core sequence (Met-Glu-His-Phe) extended with a C-terminal Pro-Gly-Pro tripeptide. The Pro-Gly-Pro extension confers resistance to prolyl endopeptidase cleavage relative to the native ACTH(4-10) parent sequence, and the PGP fragment is the predominant brain metabolite identified in distribution studies. In-vitro work has characterized specific, calcium-dependent, reversible binding to a membrane site in rodent brain tissue, consistent with a G-protein-coupled receptor structural context. The methionine residue is oxidation-susceptible, and the histidine and N-terminal residues support copper(II) coordination chemistry studied in neuronal cell models.

Storage & Handling

Lyophilized

-20°C, protected from light and moisture; stable long term.

Handling

The methionine residue is oxidation-susceptible; protect from light/air; avoid freeze-thaw.

Primary Database

PubChem CID 9811102 ↗

References (26)

1. Reviews

   1

   Dergunova LV, Filippenkov IB, Limborska SA, Myasoedov NF. (2021). Med Res Rev

   DOI: 10.1002/med.21704

2. 2

   Dergunova LV, et al. (2020). Biochemistry (Moscow)

   DOI: 10.1134/S0006297920030037

3. 3

   Levitskaya NG, et al. (2018). Biol Bull

   DOI: 10.1134/S1062359018060055

4. 4

   Tsai SJ. (2007). Medical Hypotheses

   DOI: 10.1016/j.mehy.2006.07.017PubMed 16996699

5. Clinical

   5

   Gusev EI, et al. (2018). Zh Nevrol Psikhiatr

   DOI: 10.17116/jnevro20181183261-68PubMed 29798983

6. 6

   Lebedeva IS, et al. (2018). Bull Exp Biol Med

   DOI: 10.1007/s10517-018-4234-3PubMed 30225715

7. 7

   Kurysheva NI, et al. (2001). Zh Nevrol Psikhiatr

   PubMed 11569188

8. 8

   Polunin GS, et al. (2000). Vestn Oftalmol

   PubMed 10741256

9. 9

   Gusev EI, et al. (1997). Zh Nevrol Psikhiatr

   PubMed 11517472

10. Primary research

    10

    Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F. (2022). ACS Chem Neurosci

    DOI: 10.1021/acschemneuro.1c00707PubMed 35080861

11. 11

    Sudarkina OY, et al. (2021). Int J Mol Sci

    DOI: 10.3390/ijms22126179PubMed 34201112

12. 12

    Filippenkov IB, et al. (2020). Genes (Basel)

    DOI: 10.3390/genes11060681PubMed 32580520

13. 13

    Dergunova LV, Filippenkov IB, et al. (2018). BMC Genomics

    DOI: 10.1186/s12864-018-5039-5

14. 14

    Medvedeva EV, Dmitrieva VG, et al. (2017). Mol Genet Genomics

    DOI: 10.1007/s00438-017-1297-1

15. 15

    Medvedeva EV, et al. (2014). BMC Genomics

    DOI: 10.1186/1471-2164-15-228PubMed 24661604

16. 16

    Manchenko DM, et al. (2012). Neurosci Behav Physiol

    DOI: 10.1007/s11055-012-9562-6

17. 17

    Agniullin YaV, et al. (2009). J Mol Neurosci

    DOI: 10.1007/s12031-009-9270-zPubMed 19662538

18. 18

    Shadrina MI, et al. (2007). Neurosci Lett

    PubMed 17353092

19. 19

    Dolotov OV, et al. (2006). Brain Res

    PubMed 16996037

20. 20

    Dolotov OV, et al. (2006). J Neurochem

    DOI: 10.1111/j.1471-4159.2006.03658.xPubMed 16635254

21. 21

    Shevchenko KV, et al. (2006). Russ J Bioorg Chem

    DOI: 10.1134/S1068162006010055PubMed 16523722

22. 22

    Eremin KO, et al. (2005). Neurochem Res

    DOI: 10.1007/s11064-005-8826-8PubMed 16362768

23. 23

    Levitskaya NG, et al. (2004). Neurosci Behav Physiol

    DOI: 10.1023/b:neab.0000018752.59465.28PubMed 15341218

24. 24

    Kost NV, et al. (2001). Russ J Bioorg Chem

    DOI: 10.1023/A:1011373002885

25. 25

    Bashkatova VG, et al. (2001). Brain Res

    DOI: 10.1016/S0006-8993(00)03324-2PubMed 11245825

26. 26

    Adan RAH, et al. (1994). Eur J Pharmacol

    PubMed 7895772